Biogen Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones05:54

DJ Biogen Inc. Stock Underperforms Monday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Biogen Inc. $(BIIB)$ slipped 1.82% to $249.01 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.41% to 51,983.98 and the S&P 500 Index falling 0.51% to 7,541.40.

The stock's fall snapped a two-day winning streak.

Biogen Inc. closed 3.78% short of its 52-week high of $258.78, which the company reached on October 28th.

The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson $(JNJ)$ fell 0.97% to $270.56, Pfizer Inc. $(PFE)$ rose 0.49% to $30.67, and AbbVie Inc. $(ABBV)$ fell 2.05% to $288.84.

Data source: Dow Jones Market Data, FactSet. Data compiled November 2, 2026.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment